Asparaginase Escherichia coli
- Generic Name
- Asparaginase Escherichia coli
- Brand Names
- Rylaze, Spectrila
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9015-68-3
- Unique Ingredient Identifier
- G4FQ3CKY5R
- Background
Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exh...
- Indication
Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 126
- Registration Number
- NCT00049569
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 1800
- Registration Number
- NCT00003437
- Locations
- 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 276
- Registration Number
- NCT00005603
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT00002756
- Locations
- 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 254
- Registration Number
- NCT00003593
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-12
- Target Recruit Count
- 392
- Registration Number
- NCT00002700
- Locations
- 🇸🇰
Institute of Hematology & Transfusiology, University Hospital, Bratislava, Slovakia
🇧🇪Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: prednisoneDrug: vincristine sulfateDrug: daunorubicin hydrochlorideDrug: asparaginaseDrug: methotrexateDrug: cyclophosphamideDrug: cytarabineDrug: mercaptopurineDrug: leucovorin calciumDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: thioguanineRadiation: radiation therapyDrug: pegaspargaseOther: pharmacological studyDrug: nelarabineOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00016302
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- Childhood Acute Erythroleukemia (M6)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Monoblastic Leukemia (M5a)Childhood Acute Monocytic Leukemia (M5b)Childhood Acute Myeloblastic Leukemia With Maturation (M2)Childhood Acute Myeloblastic Leukemia Without Maturation (M1)Childhood Acute Myelomonocytic Leukemia (M4)Childhood Myelodysplastic SyndromesChronic Myelomonocytic Leukemiade Novo Myelodysplastic Syndromes
- Interventions
- Drug: daunorubicin hydrochlorideDrug: asparaginaseDrug: therapeutic hydrocortisoneRadiation: 3-dimensional conformal radiation therapyDrug: fludarabine phosphateProcedure: allogeneic bone marrow transplantationBiological: filgrastimDrug: cytarabineDrug: idarubicinDrug: dexamethasoneBiological: aldesleukinDrug: thioguanineDrug: etoposideDrug: methotrexateDrug: cyclophosphamideDrug: busulfan
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 880
- Registration Number
- NCT00002798
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: filgrastimDrug: asparaginaseDrug: cyclophosphamideDrug: cyclosporineDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: etoposideDrug: ifosfamideDrug: imatinib mesylateDrug: leucovorin calciumDrug: mercaptopurine tabletDrug: methotrexateDrug: pegaspargaseDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 220
- Registration Number
- NCT00022737
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 47
- Registration Number
- NCT00028899
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸CancerCare of Maine at Eastern Maine Medial Center, Bangor, Maine, United States
🇺🇸Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.